New findings provide hope for treatment of multiple myeloma

Published by W Butcher on

Multiple Myeloma (MM) is a heterogeneous cancer disease comprised of various distinct subtypes and accounts for nearly 20 percent of deaths caused by all blood related diseases. Treatment of this disease has improved over the last decades, however some patients continue to experience multiple relapses, which contribute to premature deaths. In this study on 25 patients, the researchers at Karolinska Institutet found that a dose of 400 mg daily of venetoclax, a medication currently used to treat different types of leukemia, was effective in the treatment of heavily pre-treated MM and AL-amyloidosis patients, a disease associated with plasma cell dyscrasia, with mild manageable adverse events and no associated deaths.

Read More…

Categories: Uncategorized

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published.